Analyst Ratings For China Biologic Products (NASDAQ:CBPO)
Today, Jefferies Group reiterated its Buy rating on China Biologic Products (NASDAQ:CBPO) with a price target of $97.00.
Some recent analyst ratings include
- 3/15/2018-Jefferies Group Reiterated Rating of Buy.
- 5/30/2017-Goldman Sachs Group initiated coverage with a Neutral rating.
- 3/3/2017-Morgan Stanley Reiterated Rating of Overweight.
- 7/5/2016-Credit Suisse Group Upgrade from a “Neutral ” rating to a ” Outperform” rating.
Recent Insider Trading Activity For China Biologic Products (NASDAQ:CBPO)
China Biologic Products (NASDAQ:CBPO) has insider ownership of 2.73% and institutional ownership of 56.27%.
- On 5/9/2017 Zhijing Cbpo Liu, Insider, sold 7,500 with an average share price of $116.49 per share and the total transaction amounting to $873,675.00.
- On 3/2/2017 Sean Shao, Director, sold 20,000 with an average share price of $100.78 per share and the total transaction amounting to $2,015,600.00.
- On 3/1/2017 David Gao, CEO, sold 116,653 with an average share price of $100.63 per share and the total transaction amounting to $11,738,791.39.
- On 8/15/2016 Ming Yang, CFO, sold 21,092 with an average share price of $124.32 per share and the total transaction amounting to $2,622,157.44.
- On 8/15/2016 Wenfang Liu, Director, sold 2,900 with an average share price of $124.32 per share and the total transaction amounting to $360,528.00.
- On 8/15/2016 Zhijing Cbpo Liu, Insider, sold 1,968 with an average share price of $124.32 per share and the total transaction amounting to $244,661.76.
- On 6/8/2016 Wp X Biologics Llc, Director, sold 2,775,000 with an average share price of $111.00 per share and the total transaction amounting to $308,025,000.00.
Recent Trading Activity for China Biologic Products (NASDAQ:CBPO)
Shares of China Biologic Products closed the previous trading session at with shares trading hands.